Verici Dx (AIM: VRCI) secures £8.75m as investors confront major share dilution

Verici Dx plc (AIM: VRCI), the kidney transplant diagnostics developer with operations focused on the United States healthcare market, has announced a £8.75 million equity fundraising alongside the restoration of trading in its ordinary shares on AIM. The announcement on 13 October 2026 follows a financing process that began earlier in the month and will significantly expand the company’s issued share capital. The proceeds are intended to support the commercial rollout of Tutivia, its kidney transplant rejection-risk assessment test, while financing laboratory capacity, sales expansion and additional working capital.

The transaction brings an important financial consequence for existing shareholders. Based on the announced share issuance figures, the company’s issued share capital could increase from approximately 2.29 billion shares before the fundraising to 6.66 billion following admission of all the new placing and retail offer shares. That would leave the original shares representing approximately 34.3% of the enlarged issued share capital, equivalent to a reduction of approximately 65.7% in their collective ownership percentage, assuming the remaining conditional issuance proceeds.

The distinction between financial survival, commercial growth and per-share value creation is particularly important for Verici Dx. The company has demonstrated encouraging growth in testing revenues, but it continues to report operating losses and substantial cash outflows. Shareholders must therefore evaluate whether the additional capital can help the business reach sustainable commercial scale before further financing becomes necessary.

How much dilution will Verici Dx shareholders face after the £8.75 million fundraising?

Verici Dx priced the fundraising at 0.2 pence per ordinary share, comprising institutional placing shares and shares offered through the Winterflood Retail Access Platform. The company announced a placing of approximately 4.25 billion shares and a retail offer of approximately 125 million shares. Together, these represent approximately 4.375 billion newly issued shares once the fundraising has been fully implemented.

The financing is structured in stages. Approximately 1.683 billion firm placing shares were scheduled for admission on 13 October, increasing the total issued share capital to approximately 3.97 billion shares. A further 2.567 billion conditional placing shares and approximately 125 million retail offer shares are expected to be admitted around 28 October, subject to shareholder approval at the general meeting scheduled for 27 October.

This structure creates a distinction between the shares already eligible for admission under existing authorities and those requiring additional shareholder approval. Although Verici Dx has announced aggregate gross proceeds of £8.75 million, investors should not treat every element of the conditional issuance as already completed. The timing and availability of the remaining capital depend on satisfying the relevant conditions.

The dilution is substantial in percentage terms. Before the fundraising, the company had approximately 2.287 billion ordinary shares outstanding, based on the announced post-first-admission share count. Adding approximately 4.375 billion shares would increase the issued base to approximately 6.662 billion, making newly issued shares account for roughly two-thirds of the enlarged total.

This calculation concerns issued ordinary shares and excludes any additional dilution that could arise from options, warrants or other instruments not incorporated into those figures. It also does not mean that the market value of an individual investment automatically falls by 65.7%, because the company receives additional capital in exchange for the new shares. The economic outcome depends on how effectively that capital contributes to future revenue, profitability and enterprise value.

Can Tutivia revenue growth justify the scale of Verici Dx’s new financing?

Verici Dx’s commercial case rests principally on Tutivia, a blood-based diagnostic test intended to support the assessment of rejection risk in kidney transplant recipients. The company is working to expand adoption among transplant centres, increase recurring testing volumes and develop reliable reimbursement and collection processes. Its financial performance increasingly depends on how effectively those activities translate into recognised revenue and cash receipts.

The six months ended 30 June 2026 provided evidence of progress in testing activity. Verici Dx reported approximately $1.8 million in total revenue, compared with $1.9 million in the corresponding period of 2025. However, testing revenue increased from approximately $1.16 million to $1.76 million, demonstrating underlying growth of just over 50%.

The difference between total revenue and testing revenue is important. The previous-year period benefited from approximately $750,000 in licensing revenue that was not repeated in the first half of 2026. Consequently, the decline in reported total revenue did not reflect a comparable deterioration in the underlying Tutivia testing business.

Verici Dx also reported that its active network had expanded to 36 transplant centres, collectively accounting for more than 23% of annual kidney transplant procedures performed in the United States. That is a potentially important indicator of market access, but it does not mean that Tutivia is already used in 23% of transplant procedures. Actual commercial penetration will depend on how frequently participating centres order tests, how broadly the test is adopted within clinical protocols and whether reimbursements are collected.

The company has projected approximately $4.75 million in Tutivia revenue for the year ending 31 December 2026. This is a management expectation rather than an achieved financial result, and delivery will depend on continued commercial execution during the second half. Revenue growth at that scale would represent meaningful progress, but it would not by itself establish that the business has reached cash-flow breakeven.

Why is reimbursement becoming a critical financial variable for Verici Dx?

The commercial performance of a specialised diagnostic test depends on more than the number of tests ordered or completed. Laboratories must also establish the amount expected to be reimbursed, the likelihood of collecting that amount and the timing of payment. These factors can create substantial differences between revenue recognised in financial statements and cash received from insurers or other payers.

Verici Dx disclosed that Medicare and Medicaid accounted for approximately 68.6% of first-half 2026 revenue and 80.6% of cash collected during the period. The company also reported that average reimbursement was maintained at approximately $2,300 per test during the six months. Those figures provide useful context for the economics of the existing testing business, although the actual revenue realised from future tests will depend on payer composition and collection outcomes.

Commercial insurers present additional uncertainty. Verici Dx reported accounts receivable of approximately $2.1 million at 30 June 2026, compared with $1.5 million at the end of 2025. Management indicated that establishing arrangements with commercial payers was taking longer than previously anticipated, although it did not consider the receivables balance to represent bad debt.

This creates an important operating challenge as test volumes increase. Rapid revenue growth can still put pressure on working capital if invoices are collected slowly, especially when laboratories must pay employees, suppliers and other operating expenses before receiving reimbursement. The business therefore needs to demonstrate that increasing test adoption can be converted into dependable cash flow.

The company is also developing Protega, another kidney transplant-related diagnostic offering. Progress toward commercialisation could eventually diversify its revenue opportunities, but the product’s potential should not be treated as equivalent to established sales. Future contribution will depend on clinical adoption, reimbursement arrangements and the achievement of relevant commercial milestones.

Will Verici Dx’s new capital be sufficient to reach cash-flow breakeven in 2027?

Verici Dx ended June 2026 with approximately $2.4 million in cash, compared with $3.3 million at the end of December 2025. The company also reported a $3.5 million adjusted EBITDA loss for the first half, compared with $2.8 million a year earlier. Net cash outflow from operating activities reached approximately $3.8 million, highlighting the financial demands of expanding its diagnostic testing business.

The latest fundraising follows an earlier equity financing completed in June 2026 that generated approximately £2.6 million in gross proceeds. That earlier transaction was intended to support the company’s commercial expansion and provide working capital through the end of 2026. The additional October financing substantially increases available funding capacity, but it also demonstrates how demanding the transition from early commercial adoption to sustainable operations can be.

Management has indicated that the new financing is expected to support its growth plans and provide sufficient runway to achieve cash-flow breakeven by the end of 2027, based on internal revenue projections. The company also expects to have working capital supporting its expansion plans into FY2028 without needing further funding under those assumptions. These statements are conditional forecasts rather than guarantees about future financing requirements.

The proposed expenditure includes additional commercial personnel, marketing activity, strategic appointments and laboratory equipment. Such investments could accelerate revenue growth and increase testing capacity, but they may also maintain or increase operating expenditure before the benefits are fully realised. The effectiveness of that spending will determine how quickly the company can reduce its dependence on external capital.

A credible route to breakeven would require rising testing volumes, dependable reimbursement, improving cash collections and sufficient operating efficiency to absorb the expanded cost base. The company could achieve strong revenue growth and still require additional financing if customer adoption, payer collections or expenditure differ materially from its projections. Investors should therefore assess cash-flow performance alongside commercial revenue rather than relying on the runway guidance in isolation.

What should investors monitor after Verici Dx restores trading on AIM?

The first milestone is the shareholder vote on 27 October concerning the remaining conditional placing shares and associated retail offer issuance. Approval would enable the planned second admission and complete the announced expansion of the issued share capital. Until that process is concluded, the full share-count increase remains conditional.

The second milestone involves Tutivia’s commercial performance during the remainder of 2026. Investors will want evidence that the company is progressing toward its $4.75 million revenue target through genuine growth in test utilisation and recurring customer demand. Expansion in the number of participating transplant centres is encouraging, but improving revenue per active centre may ultimately provide a clearer indication of sustainable adoption.

Cash conversion represents the third important measure. A declining operating cash outflow, accompanied by improving reimbursement collections, would provide stronger evidence that additional equity capital is financing a path toward sustainability rather than merely covering recurring losses. Changes in the accounts receivable balance and payer collection periods should therefore be examined alongside reported revenue growth.

The £8.75 million fundraising gives Verici Dx additional financial resources at a critical commercial stage, but the scale of dilution creates a demanding test for management. Shareholders are exchanging a substantially smaller percentage ownership of the enlarged company for the possibility of a better-capitalised business with stronger growth prospects. Whether that exchange ultimately creates value will depend on measurable progress toward profitable operations and reduced future financing requirements.